Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Gastroenterology
Adult Congenital Heart Disease
Questions discussed in this category
Would you consider sotalol to be a suitable non-selective beta blocker for primary prevention of variceal bleeding in a patient who requires sotalol for treatment of arrhythmia in the setting of Fontan-associated liver disease and clinically significant portal hypertension?
1 Answer available
22250
Papers discussed in this category
Lancet (London, England), 2019 Mar 22
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.
Related Topics in Gastroenterology
Radiation Oncology
Gynecologic Oncology
Palliation
Gastrointestinal Cancers
Genitourinary Cancers
Melanoma/Skin Cancer
Pediatric Hematology/Oncology
Thoracic Malignancies
Esophageal Cancer
Medical Oncology